Local News: Oscoda, MI 

 | 

Sign Up

 | 

Sign In

Advertisment

Novartis News Editors

RoboBlogger

I edit this news page on Topix when no humans are available to help.

People just like you make Novartis News on Topix better every day. If you're interested in becoming an editor, apply today!

Edits History | Editor Blog

RSS icon mobile icon

Novartis News

News on Novartis continually updated from thousands of sources around the net.

Yesterday | The Motley Fool

Novartis Didn't Know JAK, Until Now

David Gardner called it. Hea s up 1,334%! See what Davida s recommending that you buy NEXT.

Comment?

Related Topix: Biotech, Incyte, Healthcare Industry, Johnson and Johnson

Sat Nov 28, 2009

MediLexicon

Novartis Gains Rights To Two Oral Targeted Investigational Therapies...

Novartis has gained exclusive rights to two oral targeted investigational therapies for patients with a range of life-threatening blood disorders and cancers that currently do not have effective treatment options.

Comment?

Related Topix: Biotech, Medicine, Cancer, Health, Lung Cancer, Oncology

Fri Nov 27, 2009

Market Watch

Incyte to license 2 hematology drugs to Novartis

Incyte Corp., /quotes/comstock/15*!incy /quotes/nls/incy the Wilmington, Del., drug developer focused on cancer, inflammation and diabetes, said it licensed two investigational hematology-oncology therapies to Novartis, /quotes/comstock/13*!nvs /quotes/nls/nvs /quotes/comstock/06p!novn the Basel health-care giant.

Comment?

Related Topix: Biotech, Medicine, Incyte, Healthcare Industry, Wilmington, DE, Oncology

Thu Nov 26, 2009

BioWorld

JAKs Are Better: Incyte Draws Novartis, Pfizer Face-off Next?

The deal step taken by Gleevec-experienced Novartis AG - probably Incyte Corp.'s most logical big-pharma partner outside the U.S. for its Phase III JAK1/2 inhibitor against myelofibrosis - may not have surprised many, but adding another, earlier-stage compound in the cMET inhibitor class made a nice bonus.

Comment?

Related Topix: Biotech, Medicine, Incyte, Healthcare Industry, Pfizer, Wilmington, DE

The Motley Fool

Prospecting for Stocks: Novartis

Identifying the best investment opportunities in the sector takes time. So we've built this "Prospecting" screen -- which is a simplified version of the special checklist that has helped Jeff Fischer and the Motley Fool Pro team -- to accelerate your research and help you identify companies that may make a winning addition to your portfolio.

Comment?

Related Topix: Biotech, Financial Markets, Medicine, Healthcare Industry

Wed Nov 25, 2009

Chicago Tribune

Baxter seeks to build U.S. factory

Deerfield-based Baxter International Inc. says it is looking into building a cell-based vaccine manufacturing plant in the U.S. to produce seasonal and pandemic flu vaccines.

Comment?

Related Topix: Medicine, Baxter International, Medical Equipment, Healthcare Industry, Epidemic, Influenza, Natural Disasters, Health, Biotech, H1N1 Influenza / Swine Flu, Business News

Minyanville

Tiny Incyte Gets Boost From Novartis Deal

'Tis the season for pharmaceutical deals as drug-makers try to pad their pipeline with promising compounds.

Comment?

Related Topix: Biotech, Medicine, Incyte, Healthcare Industry, Oncology

ABC News

Idera: Novartis Deal Ends, Merck Pact Extended

Idera Pharmaceuticals Inc. on Wednesday announced the end of a research partnership with Novartis AG, but said Merck & Co.

Comment?

Related Topix: Biotech, Merck , Medicine, Healthcare Industry, Idera Pharmaceuticals

BusinessWeek

How Big Pharma Profits from Swine Flu

Swiss pharmaceutical giant Novartis gave U.S. efforts to combat pandemic influenzas a boost with the Nov.

Comment?

Related Topix: H1N1 Influenza / Swine Flu, Health, Biotech, Epidemic, Natural Disasters, Medicine, Influenza, Food and Drug Administration

Tue Nov 24, 2009

The American

Investing in India: Art of the Impossible?

Herea s how India will become the place for future investment and future pharmacological breakthroughs.

Comment?

Related Topix: World News, India, Asia, Manmohan Singh, Biotech,

The Plain Dealer

Novartis: 1st US plant for cell-based flu vaccine

BASEL, Switzerland - Swiss pharmaceuticals maker Novartis AG has opened the first U.S. plant to produce flu vaccines using cell cultures instead of egg-based methods, it said Tuesday.

Comment?

Related Topix: Medicine, Influenza, Health, Biotech, Holly Springs, NC, H1N1 Influenza / Swine Flu

TheStreet.com

'Mad Money Lightning Round': Ciena's a Bargain

Here's what Jim Cramer had to say about some of the stocks that callers offered up during the "Mad Money Lightning Round" Monday evening.

Comment?

Related Topix: Mad Money, Entertainment, Television, CIENA, Telecom, Financial Markets, VimpelCommunications, Biotech, SanofiSynthlabo

Mon Nov 23, 2009

Drugs.com

Novartis Increases Staff Pay by 1.5% from April 2010

From M2 Europharma 20 November 2009 - Swiss drug maker Novartis AG said Friday it will raise the payments of its employees in Basel and in the plants in the Rheine valley by an average of 1.5% as of April 2010.

Comment?

Related Topix: Biotech, Lymphoma, Health, Leukemia, Medicine, Influenza, H1N1 Influenza / Swine Flu

Sun Nov 22, 2009

Apex Herald

Opening ceremony for Novartis facility Nov. 24

The opening ceremony for the first large-scale US Flu Cell Culture and adjuvant manufacturing facility, developed in partnership with the U.S. Department of Health and Human Services, will be held Tues.

Comment?

Related Topix: Biotech, Holly Springs, NC, Epidemic, Natural Disasters, Centers for Disease Control and Prevention, Medicine, Influenza, Health

Sat Nov 21, 2009

Tech Confidential Blog

Deal Economy 2010: Novartis' Sullivan on cross-border deals

Marvelle Sullivan, the head of corporate legal M&A at Novartis AG , spoke at The Deal Economy 2010 conference on Wednesday in New York City.

Comment?

Related Topix: Biotech

Thu Nov 19, 2009

Bloomberg.com

Flu Shot Made From Caterpillars May Win Pivotal Backing of U.S. Advisers

Protein Sciences Corp. may win backing from a U.S. panel today for a flu vaccine that can be produced in a third of the time it takes Sanofi-Aventis SA , GlaxoSmithKline Plc and Novartis AG to make their shots.

Comment?

Related Topix: Biotech, Entomology, Science, Epidemic, Natural Disasters, Mayo Clinic College of Medicine, Food and Drug Administration, Centers for Disease Control and Prevention

MarketWatch

Pfizer reportedly to sell generic drugs in Japan

Pfizer Inc. plans to release generic drugs in Japan as early as 2011, expecting demand to increase as industrialized nations intensify efforts to control drug prices, according to a report Thursday.

Comment?

Related Topix: Pfizer, Biotech, Medicine, Healthcare Industry

Wed Nov 18, 2009

Investopedia

Four Healthcare Stocks On Fire

A fair amount of uncertainty continues to surround the healthcare sector as Congress debates how it can improve the existing system in the U.S. , but that has not prevented a number of stocks in the space from storming up the charts.

Comment?

Related Topix: Financial Markets, Biotech, Medicine, Exelixis, Healthcare Industry, SanofiSynthlabo, Bristol Myers Squibb, Medical Equipment, Intuitive Surgical

Tue Nov 17, 2009

M2.com

Novartis unveils Prevacid24HR Over-the-Counter in US for frequent heartburn treatment

Healthcare solutions provider Novartis declared on Thursday the launch of Prevacid24HR over-the-counter in pharmacies and retail stores across the US to treat frequent heartburn.

Comment?

Related Topix: Heartburn, Medicine, Health, Biotech, Food and Drug Administration

Sun Nov 15, 2009

Seattle's WB

Novartis to Ship 30 Million Vaccine Doses

Swiss drugmaker Novartis AG said Thursday it is on track to meet its U.S. government order for swine flu vaccine, seeking to calm fears in recent weeks that shipments and vaccination programs may be delayed.

Comment?

Related Topix: Biotech, Medicine, H1N1 Influenza / Swine Flu, Health, Influenza

Click Here

Oscoda Jobs

Also on Topix